Key result
In diabetes, angiogenesis is regulated in an organ-, tissue-, and cell type-specific manner, requiring locally acting or tissue-specific targeted therapies to treat diabetic angiopathy.
This review highlights the role of abnormal angiogenesis in diabetic vascular complications and its potential as a therapeutic target.
Answers are grounded in this paper and cite their sources.
Angiogenesis modulation in diabetic vascular disease warrants caution; leaves open optimal targets for prospective trials.
Diabetes is one of the most serious health problems in the world. A major complication of diabetes is blood vessel disease, termed angiopathy, which is characterized by abnormal angiogenesis. In this review, we focus on angiogenesis abnormalities in diabetic complications and discuss its benefits and drawbacks as a therapeutic target for diabetic vascular complications. Additionally, we discuss glucose metabolism defects that are associated with abnormal angiogenesis in atypical diabetic complications such as cancer.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2012) conducted a review in Diabetic angiopathy and angiogenic defects. Angiogenesis modification therapies (e.g., anti-VEGF) was evaluated. In diabetes, angiogenesis is regulated in an organ-, tissue-, and cell type-specific manner, requiring locally acting or tissue-specific targeted therapies to treat diabetic angiopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: